BMS309403
| 中文名称 | BMS309403 |
|---|---|
| 中文同义词 | 2-[[2'-(5-乙基-3,4-二苯基-1H-吡唑-1-基)[1,1'-联苯]-3-基]氧基]乙酸;2-(5-乙基-3,4-二苯基-吡唑-1-基)-联苯-3-基氧基]乙酸;2'-(5-乙基-3,4-二苯基-吡唑-1-基)-双苯基-3-氧基]乙酸;化合物BMS-309403;INHIBITOR|||BMS309403|||SELECTIVE|||BMS 309403|||BMS-309403|||ORAL|||FATTY ACID-BINDING PROTEIN|||INHIBIT|||BMS-309403|||BMS 309403|||ENDOTHELIAL|||UPTAKE|||GLUCOSE|||FABP|||BMS309403|||FUNCTION;化合物BMS-309403,10 MM DMSO 溶液;BMS-309403抑制剂;抑制剂2-((2'-(5-Ethyl-3,4-diphenyl-1H-pyrazol-1-yl)-[1,1'-biphenyl]-3-yl)oxy)acetic acid |
| 英文名称 | 2''-(5-ETHYL-3,4-DIPHENYL-PYRAZOL-1-YL)-BIPHENYL-3-YLOXY]ACETIC ACID |
| 英文同义词 | 2''-(5-ETHYL-3,4-DIPHENYL-PYRAZOL-1-YL)-BIPHENYL-3-YLOXY]ACETIC ACID;2-[[2'-(5-ethyl-3,4-diphenyl-1H-pyrazol-1-yl)[1,1'-biphenyl]-3-yl]oxy]- acetic acid;BMS309403;3-[2-(5-ETHYL-3,4-DIPHENYLPYRAZOL-1-YL)PHENYL]PHENOXYACETIC ACID;CS-495;BMS 309403;BMS309403;Acetic acid, 2-[[2'-(5-ethyl-3,4-diphenyl-1H-pyrazol-1-yl)[1,1'-biphenyl]-3-yl]oxy]-;2-[3-[2-(5-ethyl-3,4-diphenylpyrazol-1-yl)phenyl]phenoxy]acetic acid |
| CAS号 | 300657-03-8 |
| 分子式 | C31H26N2O3 |
| 分子量 | 474.55 |
| EINECS号 | |
| 相关类别 | 试剂;FABP4 Inhibitor;selective inhibitor of adipocyte Fatty-Acid-Binding Protein (aFABP/aP2) |
| Mol文件 | 300657-03-8.mol |
| 结构式 |  |
BMS309403 性质
| 沸点 | 657.5±55.0 °C(Predicted) |
|---|---|
| 密度 | 1.17 |
| 储存条件 | Sealed in dry,Room Temperature |
| 溶解度 | 可溶于 DMSO（高达至少 25 mg/ml）。 |
| 形态 | 白色粉末状固体。 |
| 酸度系数(pKa) | 3.15±0.10(Predicted) |
| 颜色 | 灰白色或浅黄色 |
| 稳定性 | 可在-20°下的DMSO中的溶液储存长达1个月。 |
| InChI | 1S/C31H26N2O3/c1-2-27-30(22-12-5-3-6-13-22)31(23-14-7-4-8-15-23)32-33(27)28-19-10-9-18-26(28)24-16-11-17-25(20-24)36-21-29(34)35/h3-20H,2,21H2,1H3,(H,34,35) |
| InChIKey | SJRVJRYZAQYCEE-UHFFFAOYSA-N |
| SMILES | C(O)(=O)COC1C=CC=C(C2=CC=CC=C2N2C(CC)=C(C3=CC=CC=C3)C(C3=CC=CC=C3)=N2)C=1 |
BMS309403是FABP4小分子抑制剂，Kd值为4 nM，对FABP4的选择性比对FABP5和FABP3高100倍以上。
| Target | Value |
|
FABP4
(Cell-free assay) | 4 nM(Kd) |
Treatment with BMS-309403 significantly decreased MCP-1 production from THP-1 macrophages in a dose- and time-dependent manner.
BMS-309403 sodium (15 mg/kg; chronic treatment; daily for 6 weeks) improves endothelial function, phosphorylated and total eNOS and reduced plasma triglyceride levels but did not affect endothelium-independent relaxations.
| Animal Model: | C57BL/6J mice (ApoE −/− mice) |
| Dosage: | 15 mg/kg |
| Administration: | Chronic treatment ; daily for 6 weeks |
| Result: | Significantly increased the phosphorylated eNOS (Ser1177) and total eNOS but not the phosphorylated to total eNOS ratio in aortae of 18 weeks old ApoE −/− mice. |
安全信息
| WGK Germany | WGK 1 |
|---|---|
| 海关编码 | 2933199090 |
| 存储类别 | 11 - 可燃固体 |
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025/12/22 | HY-101903 | BMS309403 BMS-309403 | 300657-03-8 | 5mg | 700元 |
| 2025/12/22 | HY-101903 | BMS309403 BMS-309403 | 300657-03-8 | 10mM * 1mLin DMSO | 770元 |